Description: Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Home Page: www.januxrx.com
JANX Technical Analysis
11099 North Torrey Pines Road
La Jolla,
CA
92037
United States
Phone:
858 750 4700
Officers
| Name | Title |
|---|---|
| Dr. David Alan Campbell Ph.D. | Pres, CEO & Director |
| Dr. Wayne Godfrey M.D. | Chief Medical Officer |
| Mr. Tighe M. Reardon C.F.A., CPA, CPA | Acting Chief Financial Officer |
| Mr. Tommy Diraimondo Ph.D. | Sr. Director of Research |
| Ms. Brenda Van Vreeswyk | Head of HR |
| Mr. Andy Hollman Meyer | Chief Bus. Officer |
| Mr. Charles M. Winter | Sr. VP of Chemistry, Manufacturing & Controls |
| Mr. Byron Robinson J.D., Ph.D. | Chief Strategy Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6966 |
| Price-to-Sales TTM: | 71.6674 |
| IPO Date: | 2021-06-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 56 |